(Shares of the biopharmaceutical company popped 31% following an upgrade from Goldman Sachs. The firm highlighted Sagimet could see strong gains thanks to progress on a treatment for non-alcoholic steatohepatitis.)
(The pharmaceutical stock climbed 8.6% after an earnings beat. The company reported an adjusted $2.11 per share on revenue of $8.31 billion, while analysts polled by Refinitiv forecasted $1.98 and $7.58 billion.)
(Shares of the pharmaceutical company popped 13% after trial results showed its weight-loss drug Wegovy cut the risk of heart disease by 20% in adults with obesity.)
(Home improvement retailer fell more than 1% each in premarket trading. Telsey Advisory Group downgraded both stocks to market perform earlier on Tuesday, over more cautious consumer spending and weakening housing market trends.)
(Shares of the electric automaker slid less than 1% after Lucid reported a wider than expected loss for the second quarter. The company had an adjusted loss of 42 cents per share on $151 million of revenue. Analysts surveyed by Refinitiv had penciled in a loss of 33 cents per share on $175 million of revenue. )
(Palantir Technologies slid 3.4% after the data analytics company reported its second-quarter results. Palantir reported earnings of 5 cents per share on revenue of $533 million, which was in line with expectations from analysts polled by Refinitiv.)
Source: CNBC
US Top Rating Updates on 8/8
$NextCure (NXTC.US)$was initiated at Buy by HC Wainwright & Co., announced target price at $7.
MonkeyGee
:
Don't let the premarket trick you. wait for the open to trade. many times the algo uses the premarket to set the tone for the opening because the trades are lighter during premarket which allows them to have easier control over the price. Let's see where PLTR goes this week!
MonkeyGee : Don't let the premarket trick you. wait for the open to trade. many times the algo uses the premarket to set the tone for the opening because the trades are lighter during premarket which allows them to have easier control over the price. Let's see where PLTR goes this week!